200 related articles for article (PubMed ID: 16467098)
1. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
Henson ES; Hu X; Gibson SB
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
3. Expression of ErbB2 enhances radiation-induced NF-kappaB activation.
Guo G; Wang T; Gao Q; Tamae D; Wong P; Chen T; Chen WC; Shively JE; Wong JY; Li JJ
Oncogene; 2004 Jan; 23(2):535-45. PubMed ID: 14724581
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
5. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.
Petry IB; Fieber E; Schmidt M; Gehrmann M; Gebhard S; Hermes M; Schormann W; Selinski S; Freis E; Schwender H; Brulport M; Ickstadt K; Rahnenführer J; Maccoux L; West J; Kölbl H; Schuler M; Hengstler JG
Clin Cancer Res; 2010 Jan; 16(2):451-60. PubMed ID: 20068093
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
11. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN
Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
Grazette LP; Boecker W; Matsui T; Semigran M; Force TL; Hajjar RJ; Rosenzweig A
J Am Coll Cardiol; 2004 Dec; 44(11):2231-8. PubMed ID: 15582322
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
15. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
20. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
